[ad_1]
Beximco, the country’s leading pharmaceutical company, says it will invest in SIE for vaccines under the deal. This investment will be considered as the ‘advance price’ of the vaccine. Beximco Pharmaceuticals will be the ‘exclusive distributor’ of that SIE vaccine in Bangladesh.
The deal was announced by Beximco on Friday, ten days after the government announced that Bangladesh was “ready” for a possible trial of a possible vaccine made in India.
Salman F Rahman, vice president of Beximco Group and adviser to the prime minister on private industry and investment, told bdnews24.com in the evening: “It has been confirmed by this agreement that we will also be able to bring these vaccines to Bangladesh.”
The Serum Institute of India has participated in the testing and production of vaccines manufactured by the University of Oxford and AstraZeneca. Covishield is currently being tested in Brazil, the United States, the United Kingdom, and India.
IBS has already partnered with Oxford and AstraZeneca, the Gates Foundation, and Gavi to produce more than 100 million doses of the vaccine and supply it to countries around the world.
Salman F. Rahman said: “Different countries of the world are already ‘reserving’ to receive the vaccine against the coronavirus. But why us with Oxford … The advantage of the Serum Institute is that they are not just Oxford, they are working on three vaccines. ”
Now that Beximco Pharmaceuticals has been able to bring these vaccines to Bangladesh with exclusive distribution, it has been confirmed through this agreement, Salman said.
“Now we have to negotiate with them how much we will bring, at what price, what will be the price for the private sector, what will be the price for the government.”
“There will be a section for those who want to buy with money. And for those who can afford to buy with money, it makes no sense to give the government free. The government also has limited resources. ”
According to a Beximco press release, the IBS will include Bangladesh in the list of countries that will be the first to receive a certain amount of vaccine when the Oxford-AstraZeneca vaccine is approved by the regulatory authority.
“The production capacity of the SII and the company’s previous commitments to other countries will depend on the amount of investment by Beximco Pharmaceuticals Limited and the amount of the priority supply of SII vaccines for Bangladesh.”
Beximco Pharmaceuticals will also ensure that the Bangladeshi government “meets the needs,” according to the press release.
“The government will be offered to preserve the vaccine at a price to be agreed by the government of Bangladesh and the SII,” he said. Beximco Pharmaceuticals Limited will also guarantee the supply of vaccines to the private market in Bangladesh. ”
Coronavirus vaccines from various companies in China, the United States and the United Kingdom are now in the third stage of testing.
Meanwhile, the government has given permission to carry out the third phase of testing of the vaccine manufactured by China’s Sinovac Biotech Limited in Bangladesh.
According to the announcement, the experimental application of the Chinese vaccine in Bangladesh will be carried out by the International Center for Diarrhea Research ICDDR, B. The vaccine is expected to be tested in healthcare workers in the country for 18 months.
When India’s Foreign Secretary Harsh Vardhan Sringla visited Bangladesh recently, he also spoke about the Indian-made vaccine.
Following the bilateral meeting between Bangladesh’s Foreign Secretary, Masood bin Momen, and Shringler on August 19, a press release issued by the Foreign Ministry said: Bangladesh wants to receive the vaccine at an affordable price when it is ready. “.
Bangladesh ‘Ready’ for India’s Covid Ticker Trial
Permit for the experimental application of the Chinese vaccine in Bangladesh
[ad_2]
